Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 8/2015

01-08-2015 | Commentary

The future of brown adipose tissues in the treatment of type 2 diabetes

Authors: Patrick Schrauwen, Wouter D. van Marken Lichtenbelt, Bruce M. Spiegelman

Published in: Diabetologia | Issue 8/2015

Login to get access

Abstract

The recent recognition that humans possess active depots of brown adipose tissue has boosted the interest in this tissue as a potential target for the prevention and treatment of obesity and related metabolic disorders. Furthermore, it was also revealed that brown adipose tissue (BAT) in humans may consist of so-called beige or brite adipocytes. So far, cold exposure is recognised as the strongest activator of BAT in humans, but there is much ongoing research focused on finding alternative activators of BAT. The consequences of long-term BAT activation and/or cold exposure on metabolic health are still unknown, and this represents an area of intensive research. This is one of a series of commentaries under the banner ‘50 years forward’, giving personal opinions on future perspectives in diabetes, to celebrate the 50th anniversary of Diabetologia (1965–2015).
Literature
1.
Gesner C (1551) Historiæ animalium lib. I. Tigvri, Apvd Christ Froschovervm (in Latin)
2.
Smith RE (1961) Thermogenic activity of the hibernating gland in the cold-acclimatized rat. Physiologist 4:113
3.
Nicholls DG, Bernson VS, Heaton GM (1978) The identification of the component in the inner membrane of brown adipose tissue mitochondria responsible for regulating energy dissipation. Experientia Suppl 32:89–93PubMedCrossRef
4.
Lowell BB, S-Susulic V, Hamann A et al (1993) Development of obesity in transgenic mice after genetic ablation of brown adipose tissue. Nature 366:740–742PubMedCrossRef
5.
6.
van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM et al (2009) Cold-activated brown adipose tissue in healthy men. N Engl J Med 360:1500–1508PubMedCrossRef
7.
Virtanen KA, Lidell ME, Orava J et al (2009) Functional brown adipose tissue in healthy adults. N Engl J Med 360:1518–1525PubMedCrossRef
8.
Saito M, Okamatsu-Ogura Y, Matsushita M et al (2009) High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. Diabetes 58:1526–1531PubMedCentralPubMedCrossRef
9.
Ravussin E, Lillioja S, Knowler WC et al (1988) Reduced rate of energy expenditure as a risk factor for body-weight gain. N Engl J Med 318:467–472PubMedCrossRef
10.
Vosselman MJ, van Marken Lichtenbelt WD, Schrauwen P (2013) Energy dissipation in brown adipose tissue: from mice to men. Mol Cell Endocrinol 379:43–50PubMedCrossRef
11.
Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671PubMedCentralPubMedCrossRef
12.
Phielix E, Meex R, Ouwens DM et al (2012) High oxidative capacity due to chronic exercise training attenuates lipid-induced insulin resistance. Diabetes 61:2472–2478PubMedCentralPubMedCrossRef
13.
Bartelt A, Bruns OT, Reimer R et al (2011) Brown adipose tissue activity controls triglyceride clearance. Nat Med 17:200–205PubMedCrossRef
14.
15.
16.
Cohen P, Levy JD, Zhang Y et al (2014) Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell 156:304–316PubMedCentralPubMedCrossRef
17.
Lichtenbelt W, Kingma B, van der Lans A, Schellen L (2014) Cold exposure–an approach to increasing energy expenditure in humans. Trends Endocrinol Metab 25:165–167PubMedCrossRef
Metadata
Title
The future of brown adipose tissues in the treatment of type 2 diabetes
Authors
Patrick Schrauwen
Wouter D. van Marken Lichtenbelt
Bruce M. Spiegelman
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 8/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-015-3611-y

Other articles of this Issue 8/2015

Diabetologia 8/2015 Go to the issue

Commentary

Vascular AGE-ing by methylglyoxal: the past, the present and the future

Commentary

Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years?

Article

Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice

Commentary

50 years forward: beta cells

Editorial

Diabetologia at 50: celebrating half a century of progress in diabetes research and care

Article

Silencing of miR-195 reduces diabetic cardiomyopathy in C57BL/6 mice
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits